Lisa Walter Analyst PerformanceVP Biotech Equity Research at Royal Bank Of CanadaLisa Walter is a stock analyst at Royal Bank Of Canada in the medical sector, covering 10 publicly traded companies. Over the past year, Lisa Walter has issued 29 stock ratings, including buy and hold recommendations. While full access to Lisa Walter's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Lisa Walter's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings29 Last 0 YearsBuy Recommendations89.66% 26 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution29RatingsDistribution of strong buy, buy, hold, and sell ratings by Lisa Walter.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.7%26 ratings Hold10.3%3 ratings Sell0.0%0 ratingsOut of 29 total stock ratings issued by Lisa Walter at Royal Bank Of Canada, the majority (89.7%) have been Buy recommendations, followed by 10.3% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ10 companiesLisa Walter, an analyst at Royal Bank Of Canada, currently covers 10 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical10 companies100.0%Lisa Walter of Royal Bank Of Canada specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE7 companies70.0%MED - DRUGS3 companies30.0% Lisa Walter's Ratings History at Royal Bank Of Canada Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMIRMMirum Pharmaceuticals5/7/2026Boost Price Target$104.03$142.00Outperform$0.0000.00% ROIEYPTEyepoint Pharmaceuticals5/7/2026Lower Price Target$13.41$37.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics5/7/2026Lower Price Target$574.57$701.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics5/6/2026Boost Price Target$18.77$34.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals5/6/2026Boost Price Target$94.66$137.00Outperform$0.0000.00% ROIOCULOcular Therapeutix5/6/2026Reiterated Rating$9.70$30.00Outperform$0.0000.00% ROIMGTXMeiraGTx4/17/2026Boost Price Target$9.89$24.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics4/7/2026Lower Price Target$13.90$30.00Outperform$0.0000.00% ROIFDMT4D Molecular Therapeutics3/19/2026Boost Price Target$8.73$35.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals3/17/2026Lower Price Target$89.85$130.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. VRDNViridian Therapeutics2/27/2026Lower Price Target$28.41$42.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics2/26/2026Boost Price Target$498.66$643.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals2/25/2026Lower Price Target$21.16$21.00Sector Perform$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/18/2026Initiated Coverage$101.30$145.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/18/2026Initiated Coverage$101.30$145.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/18/2026Upgrade$99.76Moderate Buy$0.0000.00% ROIOCULOcular Therapeutix2/5/2026Reiterated Rating$9.29$30.00Outperform$0.0000.00% ROIFDMT4D Molecular Therapeutics1/7/2026Reiterated Rating$8.00Outperform$0.0000.00% ROIMGTXMeiraGTx11/14/2025Boost Price Target$8.26$16.00Outperform$0.0000.00% ROIFDMT4D Molecular Therapeutics11/11/2025Boost Price Target$10.50$32.00Outperform$0.0000.00% ROIEYPTEyepoint Pharmaceuticals11/6/2025Boost Price Target$11.51$39.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics11/6/2025Boost Price Target$27.71$45.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics10/30/2025Boost Price Target$450.38$587.00Outperform$0.0000.00% ROIADVMAdverum Biotechnologies10/28/2025Reiterated Rating$4.24$4.00Sector Perform$0.0000.00% ROIFDMT4D Molecular Therapeutics10/21/2025Reiterated Rating$10.85$26.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics9/26/2025Initiated Coverage$425.42$569.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics8/7/2025Lower Price Target$16.72$41.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals8/1/2025Boost Price Target$23.05$19.00Sector Perform$0.0000.00% ROIEYPTEyepoint Pharmaceuticals6/17/2025Initiated Coverage$8.90$28.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenThe Goldman Sachs GroupBerenberg BankGuggenheimUBS GroupWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJefferies Financial GroupBTIG ResearchCanadian Imperial Bank of CommerceWeiss RatingsCitigroupBarclaysJPMorgan Chase & Co. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
